S. Fesik

发表

Solution structure of the cyclosporin A/cyclophilin complex by NMR

Y. Thériault, T. Logan, R. Meadows, 1993, Nature.

Abstract 1813: Evaluation of TBK1 as a novel cancer target in the K-Ras pathway

S. Fesik, B. Vangamudi, Aimee E. Ayres, 2012 .

Discovering High-Affinity Ligands for Proteins: SAR by NMR

P. Hajduk, R. Meadows, S. Fesik, 1996, Science.

Heteronuclear three-dimensional NMR spectroscopy of the inflammatory protein C5a.

S. Fesik, E. Zuiderweg, 1989, Biochemistry.

Chk1 Mediates S and G2 Arrests through Cdc25A Degradation in Response to DNA-damaging Agents*

A. Gunasekera, S. Fesik, Zehan Chen, 2003, Journal of Biological Chemistry.

Promoting apoptosis as a strategy for cancer drug discovery

Stephen W. Fesik, S. Fesik, 2005, Nature Reviews Cancer.

14-3-3 proteins and survival kinases cooperate to inactivate BAD by BH3 domain phosphorylation.

S R Datta, M E Greenberg, Alexander Y Katsov, 2000, Molecular cell.

Kinome siRNA-phosphoproteomic screen identifies networks regulating AKT signaling

Luay Nakhleh, Yiling Lu, Kakajan Komurov, 2011, Oncogene.

NMR structure and mutagenesis of the Fas (APO-1/CD95) death domain

Stephen W. Fesik, Edward T. Olejniczak, R. Meadows, 1996, Nature.

An inhibitor of Bcl-2 family proteins induces regression of solid tumours

S. Korsmeyer, A. Letai, P. Hajduk, 2005, Nature.

NMR structure-based drug design

S. Fesik, S W Fesik, Stephen W. Fesik, 1993, Journal of biomolecular NMR.

Discovering High-Affinity Ligands for Proteins

P. Hajduk, R. Meadows, S. Fesik, 1997, Science.

siRNA-mediated gene silencing: a global genome view.

S. Fesik, D. Semizarov, P. Kroeger, 2004, Nucleic acids research.

Discovery and Design of Novel HSP90 Inhibitors Using Multiple Fragment‐based Design Strategies

Jean M. Severin, P. Hajduk, J. R. Huth, 2007, Chemical biology & drug design.

Drugging the undruggable RAS: Mission Possible?

S. Fesik, C. Der, Ji Luo, 2014, Nature Reviews Drug Discovery.

Rationale for Bcl‐XL/Bad peptide complex formation from structure, mutagenesis, and biophysical studies

A. Petros, R. Meadows, E. Olejniczak, 2000, Protein science : a publication of the Protein Society.

Druggability indices for protein targets derived from NMR-based screening data.

P. Hajduk, J. R. Huth, S. Fesik, 2005, Journal of medicinal chemistry.

NMR-based discovery of lead inhibitors that block DNA binding of the human papillomavirus E2 protein.

P. Hajduk, D. Egan, T. Holzman, 1997, Journal of medicinal chemistry.

Discovery of Potent Nonpeptide Inhibitors of Stromelysin Using SAR by NMR

Jean M. Severin, S. Davidsen, P. Hajduk, 1997 .

Structure of Bcl-xL-Bak Peptide Complex: Recognition Between Regulators of Apoptosis

R. Meadows, S. Fesik, C. Thompson, 1997, Science.

Specificity of short interfering RNA determined through gene expression signatures

S. Fesik, D. Halbert, D. Semizarov, 2003, Proceedings of the National Academy of Sciences of the United States of America.

X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death

R. Meadows, S. Fesik, S. Muchmore, 1996, Nature.

Structural biology of the Bcl-2 family of proteins.

A. Petros, E. Olejniczak, S. Fesik, 2004, Biochimica et biophysica acta.

Use of deuterium labeling in NMR: overcoming a sizeable problem.

S. Fesik, M. Sattler, Michael Sattler, 1996, Structure.

Discovery of a potent inhibitor of the antiapoptotic protein Bcl-xL from NMR and parallel synthesis.

P. Hajduk, A. Petros, S. Fesik, 2006, Journal of medicinal chemistry.

ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor.

C. Tse, S. Fesik, Eric F. Johnson, 2008, Cancer research.

Small molecule Mcl-1 inhibitors for the treatment of cancer.

S. Fesik, J. Belmar, 2015, Pharmacology & therapeutics.

Discovery of potent myeloid cell leukemia 1 (Mcl-1) inhibitors using fragment-based methods and structure-based design.

Brian A. Chauder, E. Olejniczak, S. Fesik, 2013, Journal of medicinal chemistry.

Evaluation of PMF scoring in docking weak ligands to the FK506 binding protein.

P. Hajduk, S. Fesik, Y. Martin, 1999, Journal of medicinal chemistry.

Discovery of a potent, selective protein tyrosine phosphatase 1B inhibitor using a linked-fragment strategy.

Gang Liu, P. Hajduk, S. Fesik, 2003, Journal of the American Chemical Society.

RNAi-based screening of the human kinome identifies Akt-cooperating kinases: a new approach to designing efficacious multitargeted kinase inhibitors

S. Fesik, V. Giranda, J. Leverson, 2006, Oncogene.

NMR structure and mutagenesis of the inhibitor-of-apoptosis protein XIAP

Stephen W. Fesik, A. Gunasekera, Chaohong Sun, 1999, Nature.

High-throughput nuclear magnetic resonance-based screening.

P. Hajduk, S. Fesik, D. Marek, 1999, Journal of medicinal chemistry.

NMR Structure and Mutagenesis of the Third Bir Domain of the Inhibitor of Apoptosis Protein XIAP*

Stephen W. Fesik, A. Gunasekera, Chaohong Sun, 2000, The Journal of Biological Chemistry.

Non-peptidic small molecule inhibitors of XIAP.

Chaohong Sun, R. Meadows, E. Olejniczak, 2005, Bioorganic & medicinal chemistry letters.

Privileged molecules for protein binding identified from NMR-based screening.

P. Hajduk, S. Fesik, J. Praestgaard, 2000, Journal of medicinal chemistry.

One-Dimensional Relaxation- and Diffusion-Edited NMR Methods for Screening Compounds That Bind to Macromolecules

Stephen W. Fesik, Philip J. Hajduk, P. Hajduk, 1997 .

Heteronuclear NMR studies of 13C-labeled yeast cell wall β-glucan oligosaccharides

Liping Yu, S. Fesik, G. Walker, 1993, Journal of biomolecular NMR.

NMR Structure and Mutagenesis of the N-Terminal Dbl Homology Domain of the Nucleotide Exchange Factor Trio

Hong Wang, R. Meadows, E. Olejniczak, 1998, Cell.

A METHOD FOR ASSIGNING PHENYLALANINES IN PROTEINS

S. Fesik, D. Janowick, Xiaohong Liu, 1999 .

NMR-driven discovery of benzoylanthranilic acid inhibitors of far upstream element binding protein binding to the human oncogene c-myc promoter.

G. Clore, P. Hajduk, J. R. Huth, 2004, Journal of medicinal chemistry.

Chapter 29. Macromolecular X-Ray Crystallography and NMR as Tools for Structure-based Drug Design

S. Fesik, J. Erickson, 1992 .

Conformation of an FK506 analog in aqueous solution is similar to the FKBP-bound conformation of FK506

A. Petros, S. Fesik, Heng Liang, 1993 .

Drugging an undruggable pocket on KRAS

M. Koegl, S. Fesik, A. Waterson, 2019, Proceedings of the National Academy of Sciences.

Defining the p53 DNA‐binding domain/Bcl‐xL‐binding interface using NMR

A. Gunasekera, A. Petros, E. Olejniczak, 2004, FEBS letters.

Backbone dynamics of a two-domain protein: 15N relaxation studies of the amino-terminal fragment of urokinase-type plasminogen activator.

A. Petros, R. Meadows, S. Fesik, 1994, Biochemistry.

Multidimensional NMR Studies of Immunosuppressant/Immunophilin Complexes

S. Fesik, P. Neri, 1993 .

Discovery of Inhibitors of Protein–Protein Interactions Using Fragment‐Based Methods

Stephen W. Fesik, S. Fesik, Feng Wang, 2016 .

Conformational energy differences between side chain alkylated analogues of the hallucinogen 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane.

D. E. Nichols, S. Fesik, A. Makriyannis, 1980, Journal of medicinal chemistry.

forms an inactivating dimer with Bcl-XL . Bad is a BH 3 domain-containing protein

S. Fesik, C. Thompson, J. Harlan, 1997 .

Human Chk1 expression is dispensable for somatic cell death and critical for sustaining G2 DNA damage checkpoint.

S. Fesik, S. Ng, Zehan Chen, 2003, Molecular cancer therapeutics.

Discovery of Quinazolines That Activate SOS1-Mediated Nucleotide Exchange on RAS.

S. Fesik, A. Waterson, O. Rossanese, 2018, ACS medicinal chemistry letters.

A small-molecule inhibitor of Bcl-XL potentiates the activity of cytotoxic drugs in vitro and in vivo.

Wang Shen, Mary K Joseph, Saul H Rosenberg, 2006, Cancer research.

Discovery and structure-activity relationship of antagonists of B-cell lymphoma 2 family proteins with chemopotentiation activity in vitro and in vivo.

A. Petros, S. Fesik, S. Ng, 2006, Journal of medicinal chemistry.

Efficient Multispin Homonuclear Double-Quantum Recoupling for Magic-Angle Spinning NMR: 13C−13C Correlation Spectroscopy of U-13C-Erythromycin A

C. Rienstra, S. Fesik, R. Griffin, 1998 .

Evidence for a requirement for both phospholipid and phosphotyrosine binding via the Shc phosphotyrosine-binding domain in vivo

J. C. Pratt, S. Fesik, K. Ravichandran, 1997, Molecular and cellular biology.

Binding Affinities of Tyrosine-phosphorylated Peptides to the COOH-terminal SH2 and NH-terminal Phosphotyrosine Binding Domains of Shc (*)

S. Fesik, Ming-Ming Zhou, K. Ravichandran, 1996, The Journal of Biological Chemistry.

Discovery of 2-Indole-acylsulfonamide Myeloid Cell Leukemia 1 (Mcl-1) Inhibitors Using Fragment-Based Methods.

E. Olejniczak, S. Fesik, O. Rossanese, 2016, Journal of medicinal chemistry.

Hypoxia-Inducible Factor-1 Inhibition in Combination with Temozolomide Treatment Exhibits Robust Antitumor Efficacy In vivo

S. Fesik, D. Albert, A. Shoemaker, 2006, Clinical Cancer Research.

Evidence for a role for the phosphotyrosine-binding domain of Shc in interleukin 2 signaling.

S. Fesik, S. Shoelson, K. Ravichandran, 1996, Proceedings of the National Academy of Sciences of the United States of America.

Growth inhibition and radiosensitization of glioblastoma and lung cancer cells by small interfering RNA silencing of tumor necrosis factor receptor-associated factor 2.

Dafydd G. Thomas, S. Fesik, Yi Sun, 2008, Cancer research.

Discovery and Structure-Based optimization of potent and selective WDR5 inhibitors containing a dihydroisoquinolinone bicyclic core

S. Fesik, R. Coffey, J. Sai, 2020 .

Expression, refolding, and isotopic labeling of human serum albumin domains for NMR spectroscopy.

A. Gunasekera, S. Fesik, H. Mao, 2000, Protein expression and purification.

An improved method for selectively observing protons attached to 12C in the presence of 1H13C spin pairs

E. Olejniczak, S. Fesik, G. Gemmecker, 1992 .

Rational design of diflunisal analogues with reduced affinity for human serum albumin.

P. Hajduk, S. Fesik, R. Bell, 2001, Journal of the American Chemical Society.

Developing Lipid Nanoparticle-Based siRNA Therapeutics for Hepatocellular Carcinoma Using an Integrated Approach

S. Fesik, Xiaoyu Lin, A. Sarthy, 2013, Molecular Cancer Therapeutics.

Tumor vasculature is a key determinant for the efficiency of nanoparticle-mediated siRNA delivery

S. Fesik, Xiaoyu Lin, L. Li, 2011, Gene Therapy.

Synthesis and FKBP binding of small molecule mimics of the tricarbonyl region of FK506

A. Petros, S. Fesik, Gary T. Wang, 1994 .

Multidimensional NMR studies of immunosuppressants and their binding proteins

A. Petros, Y. Thériault, T. Logan, 1993 .

PREPARATION OF BIOLOGICALLY ACTIVE RISTOCETIN DERIVATIVES: REPLACEMENTS OF THE 1′-AMINO GROUP

S. Fesik, J. Mao, T. Herrin, 1985 .

Preparation of biologically active ristocetin derivatives: replacements of the 1'-amino group.

S. Fesik, J. Mao, T. Herrin, 1985, Journal of medicinal chemistry.

Chk 1 Mediates S and G 2 Arrests through Cdc 25 A Degradation in Response to DNA-damaging Agents *

A. Gunasekera, S. Fesik, Zehan Chen, 2003 .

Structure and function of the phosphotyrosine binding (PTB) domain.

S. Fesik, M. Zhou, M. Zhou, 1995, Progress in biophysics and molecular biology.

A robust in vivo positive-readout system for monitoring siRNA delivery to xenograft tumors.

S. Fesik, Xiaoyu Lin, Yu Shen, 2011, RNA.

Determining the structure of a glycopeptide-Ac2-Lys-D-Ala-D-Ala complex using NMR parameters and molecular modeling

E. Olejniczak, S. Fesik, R. Gampe, 1986 .

A liquid crystalline medium for measuring residual dipolar couplings over a wide range of temperatures

R. Meadows, E. Olejniczak, S. Fesik, 1998 .

Phosphatidylinositol 4,5-Bisphosphate Binding to the Pleckstrin Homology Domain of Phospholipase C-δ1 Enhances Enzyme Activity*

S. Fesik, J. Lomasney, Y. Kuan, 1996, The Journal of Biological Chemistry.

Polycation binding to isolated lipopolysaccharide from antibiotic-hypersusceptible mutant strains of Escherichia coli

S. Fesik, W. Rocque, A. Haug, 1988, Antimicrobial Agents and Chemotherapy.

Role of protonated and neutral forms of macrolides in binding to ribosomes from gram-positive and gram-negative bacteria

S. Fesik, R. Goldman, C. C. Doran, 1990, Antimicrobial Agents and Chemotherapy.

Structural Elucidation of Peptide Binding to KLHL-12, a Substrate Specific Adapter Protein in a Cul3-Ring E3 Ligase Complex.

E. Olejniczak, S. Fesik, J. Sai, 2020, Biochemistry.

Solution structure of the DNA-binding domain of a human papillomavirus E2 protein: evidence for flexible DNA-binding regions.

A. Petros, D. Egan, R. Meadows, 1996, Biochemistry.

NMR studies of [U‐13C]cyclosporin A bound to human cyclophilin B

S. Fesik, C. Walsh, G. Gemmecker, 1991, FEBS letters.

Accurate Measurement of H NH a Residual Dipolar Couplings in Proteins

A. Gunasekera, R. Meadows, E. Olejniczak, 1999 .

Identification of solvent-exposed regions of an FK-506 analog, ascomycin, bound to FKBP using a paramagnetic probe

A. Petros, S. Fesik, P. Neri, 1992, Journal of biomolecular NMR.

Structural Basis for the Inhibition of Caspase-3 by XIAP

R. Liddington, R. Schwarzenbacher, Chaohong Sun, 2001, Cell.

Determination of the anomeric specificity of the Escherichia coli CTP:CMP-3-deoxy-D-manno-octulosonate cytidylyltransferase by 13C NMR spectroscopy.

S. Fesik, W. Kohlbrenner, 1985, The Journal of biological chemistry.

Efficiency of phosphorylation of the cyclobut-G (A-69992) enantiomers by HSV-1 thymidine kinase does not correlate with their anti-herpesvirus activity.

S. Fesik, D. Norbeck, J. Erickson, 1990, Biochemical pharmacology.

Two-dimensional 1H NMR studies of rat atrial natriuretic factor(1-23).

S. Fesik, W. Holleman, T. Perun, 1985, Biochemical and biophysical research communications.

Bcl-XL represents a druggable molecular vulnerability during aurora B inhibitor-mediated polyploidization

K. Glaser, S. Fesik, Mark G. Anderson, 2010, Proceedings of the National Academy of Sciences.

Two‐Dimensional NMR studies of [Pro‐10] atrial natriuretic factor [7‐23]

S. Fesik, P. Connolly, R. Gampe, 1988, Biopolymers.

Mechanism of steroid anesthetic action: interactions of alphaxalone and delta 16-alphaxalone with bilayer vesicles.

S. Fesik, A. Makriyannis, 1983, Journal of medicinal chemistry.

Characterization of lipopolysaccharide from a heptoseless mutant of Escherichia coli by carbon 13 nuclear magnetic resonance.

S. Fesik, I. Armitage, S. Strain, 1983, The Journal of biological chemistry.

Anesthetic steroid mobility in model membrane preparations as examined by high-resolution 1H and 2H NMR spectroscopy.

S. Fesik, A. Makriyannis, C. Dimeglio, 1991, Journal of medicinal chemistry.

Death Domains and Death Effector Domains

S. Fesik, 2002 .

Decreased binding of antibiotics to lipopolysaccharides from polymyxin-resistant strains of Escherichia coli and Salmonella typhimurium

S. Fesik, E. McGroarty, A. Peterson, 1987, Antimicrobial Agents and Chemotherapy.

A 4D HCCH-TOCSY experiment for assigning the side chain1H and13C resonances of proteins

E. Olejniczak, S. Fesik, R. Xu, 1992, Journal of biomolecular NMR.

Reply to Tran et al.: Dimeric KRAS protein–protein interaction stabilizers

M. Koegl, S. Fesik, A. Waterson, 2020, Proceedings of the National Academy of Sciences.

Structure and metal-binding properties of lipopolysaccharides from heptoseless mutants of Escherichia coli studied by 13C and 31P nuclear magnetic resonance.

S. Fesik, I. Armitage, S. Strain, 1983, The Journal of biological chemistry.

Solution structure of the Shc SH2 domain complexed with a tyrosine-phosphorylated peptide from the T-cell receptor.

T. Logan, R. Meadows, S. Fesik, 1995, Proceedings of the National Academy of Sciences of the United States of America.

Recent advancements in the discovery of protein-protein interaction inhibitors of replication protein A.

S. Fesik, A. Waterson, J. D. Patrone, 2017, MedChemComm.

Increased NOEs for small molecules using mixed solvents

E. Olejniczak, S. Fesik, 1987 .

Synthesis of [u-13C,15N]-cysteine hydrochloride: An important tool for heteronuclear, multi-dimensional NMR studies of proteins

S. Fesik, R. Curley, M. Panigot, 1995 .

Fragment-based drug discovery using NMR spectroscopy

S. Fesik, M. Harner, Andreas O. Frank, 2013, Journal of Biomolecular NMR.

Band-selective heteronuclear decoupling using shaped pulses as an aid in measuring long-range heteronuclear coupling constants

S. Fesik, E. Zuiderweg, 1991 .

Novel p-arylthio cinnamides as antagonists of leukocyte function-associated antigen-1/intracellular adhesion molecule-1 interaction. 2. Mechanism of inhibition and structure-based improvement of pharmaceutical properties.

E B Reilly, J. R. Huth, E. Olejniczak, 2001, Journal of medicinal chemistry.

Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins.

Saul H Rosenberg, Xiaohong Song, Milan Bruncko, 2008, Journal of medicinal chemistry.

Identification of novel inhibitors of urokinase via NMR-based screening.

Jean M. Severin, P. Hajduk, S. Fesik, 2000, Journal of medicinal chemistry.

Discovery of Potent 2-Aryl-6,7-dihydro-5 H-pyrrolo[1,2- a]imidazoles as WDR5-WIN-Site Inhibitors Using Fragment-Based Methods and Structure-Based Design.

E. Olejniczak, S. Fesik, O. Rossanese, 2018, Journal of medicinal chemistry.

Asymmetric synthesis of 2-substituted (4S)-4-aminopyrrolidines. SN2 displacement at the 4-position of the pyrrolidine moiety

S. Fesik, T. Rosen, A. Pernet, 1988 .

NMR analysis of the structure and metal sequestering properties of metallothioneins.

S. Fesik, Y. Boulanger, I. Armitage, 1984, Environmental health perspectives.

Methoxy group conformations of phenyl methyl ethers in solution

S. Fesik, A. Makriyannis, 1982 .

Lithium chloride perturbation of cis-trans peptide bond equilibria: effect on conformational equilibria in cyclosporin A and on time-dependent inhibition of cyclophilin

Stephen W. Fesik, Daniel H. Rich, S. Fesik, 1992 .

Isotope-edited NMR of cyclosporin A bound to cyclophilin: evidence for a trans 9,10 amide bond.

D. Egan, T. Holzman, R. Simmer, 1990, Science.

Identification and Optimization of Anthranilic Acid Based Inhibitors of Replication Protein A

Brittney S. Bates, E. Olejniczak, S. Fesik, 2016, ChemMedChem.

Twenty years on: the impact of fragments on drug discovery

Harren Jhoti, Wolfgang Jahnke, Daniel A. Erlanson, 2016, Nature Reviews Drug Discovery.

MYC and MCL1 Cooperatively Promote Chemotherapy-Resistant Breast Cancer Stem Cells via Regulation of Mitochondrial Oxidative Phosphorylation.

S. Fesik, H. Gómez, K. Hutchinson, 2017, Cell metabolism.

Nuclear magnetic resonance methods for studying protein-ligand complexes.

A. Petros, S. Fesik, 1994, Methods in enzymology.

Evaluating hypoxia-inducible factor-1alpha as a cancer therapeutic target via inducible RNA interference in vivo.

M. Staver, S. Fesik, D. Semizarov, 2005, Cancer research.

Novel inhibitors of Erm methyltransferases from NMR and parallel synthesis.

P. Hajduk, A. Petros, S. Fesik, 1999, Journal of medicinal chemistry.

Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL.

Mary K Joseph, Saul H Rosenberg, Xiaohong Song, 2007, Journal of medicinal chemistry.

Accounting for spin diffusion in the analysis of 2D NOE data

E. Olejniczak, S. Fesik, R. Gampe, 1986 .

Renin inhibitors. Design and synthesis of a new class of conformationally restricted analogues of angiotensinogen.

S. Fesik, J. Greer, H. Sham, 1988, Journal of medicinal chemistry.

A general method for assigning NMR spectra of denatured proteins using 3D HC(CO)NH-TOCSY triple resonance experiments

T. Logan, E. Olejniczak, S. Fesik, 1993, Journal of biomolecular NMR.

Side chain and backbone assignments in isotopically labeled proteins from two heteronuclear triple resonance experiments

T. Logan, E. Olejniczak, S. Fesik, 1992, FEBS letters.

2D and 3D NMR spectroscopy employing carbon-13/carbon-13 magnetization transfer by isotropic mixing. Spin system identification in large proteins

F. Dahlquist, E. Olejniczak, S. Fesik, 1990 .

Two-Dimensional Nuclear Magnetic Resonance Method for Identifying the H.alpha./C.alpha. Signals of Amino Acid Residues Preceding Proline

Stephen W. Fesik, Edward T. Olejniczak, E. Olejniczak, 1994 .

Solution structure of a low molecular weight protein tyrosine phosphatase.

T. Logan, R. Meadows, S. Fesik, 1994, Biochemistry.

Backbone 1H, 13C, and 15N assignments and secondary structure of bovine low molecular weight phosphotyrosyl protein phosphatase.

Y. Thériault, T. Logan, S. Fesik, 1994, Biochemistry.

NMR studies of [U-13C]cyclosporin A bound to cyclophilin: bound conformation and portions of cyclosporin involved in binding.

D. Egan, E. Olejniczak, T. Holzman, 1994, Biochemistry.

31P and 13C NMR studies of oxygen transfer during catalysis by 3-deoxy-D-manno-octulosonate cytidylyltransferase from Escherichia coli.

S. Fesik, W. Kohlbrenner, M. Nuss, 1987, The Journal of biological chemistry.

Heteronuclear three-dimensional NMR spectroscopy of isotopically labelled biological macromolecules

S. Fesik, E. Zuiderweg, E R Zuiderweg, 1990, Quarterly Reviews of Biophysics.

Heteronuclear three-dimensional NMR spectroscopy applied to CMP-KDO synthetase (27.5 kD).

S. Fesik, E. Zuiderweg, R. Gampe, 1989, Biochemical and biophysical research communications.

Interconversion rates of tautomers of 3-deoxy-d-manno-octulosonic acid (KDO) from a quantitative analysis of two-dimensional n.m.r. exchange data

E. Olejniczak, S. Fesik, R. Gampe, 1986 .

Heteronuclear three-dimensional NMR spectroscopy. Natural abundance carbon-13 chemical shift editing of 1H-1H COSY spectra

S. Fesik, E. Zuiderweg, R. Gampe, 1989 .

Structure and ligand recognition of the phosphotyrosine binding domain of Shc

A. Petros, R. Meadows, E. Olejniczak, 1995, Nature.

Myeloid cell leukemia-1 is an important apoptotic survival factor in triple-negative breast cancer

E. Olejniczak, S. Fesik, O. Rossanese, 2015, Cell Death and Differentiation.

NMR studies of an FK-506 analog, [U-13C]ascomycin, bound to FK-506-binding protein.

A. Petros, E. Olejniczak, S. Fesik, 1992, Journal of medicinal chemistry.

Solution structure of the C-terminal single-stranded DNA-binding domain of Escherichia coli topoisomerase I.

S. Fesik, Y. Tse‐Dinh, L. Yu, 1995, Biochemistry.

Structural characterization of the interaction between a pleckstrin homology domain and phosphatidylinositol 4,5-bisphosphate.

P. Hajduk, S. Fesik, H. Yoon, 1995, Biochemistry.

Pleckstrin homology domains bind to phosphatidylinositol-4,5-bisphosphate

P. Hajduk, S. Fesik, H. Yoon, 1994, Nature.

A practical method for uniform isotopic labeling of recombinant proteins in mammalian cells.

A. Petros, S. Fesik, A. Mazar, 1992, Biochemistry.

NMR methods for determining the structures of enzyme/inhibitor complexes as an aid in drug design.

E. Olejniczak, S. Fesik, E. Zuiderweg, 1990, Biochemical pharmacology.

pH titration of the histidine residues of cyclophilin and FK506 binding protein in the absence and presence of immunosuppressant ligands.

S. Fesik, L. Yu, Liping Yu, 1994, Biochimica et biophysica acta.

Isolation and Characterization of Natural and Recombinant Cyclophilins

T. Holzman, S. Fesik, J. Kofron, 1991 .

Structural basis for IL-4 receptor phosphopeptide recognition by thelRS-1 PTB domain

R. Meadows, E. Olejniczak, S. Fesik, 1996, Nature Structural Biology.

Identification of a novel regulatory domain in Bcl‐xL and Bcl‐2

S. Fesik, S. Muchmore, C. Thompson, 1997, The EMBO journal.

‘Seed’ analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737

S. Fesik, S. Morgan-Lappe, L. Vernetti, 2007, Oncogene.

Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737.

C. Tse, S. Fesik, S. Ng, 2007, Cancer research.

Solution structure of the antiapoptotic protein bcl-2

A. Petros, S. Fesik, H. Yoon, 2001, Proceedings of the National Academy of Sciences of the United States of America.

The BH3 Domain of Bcl-xS Is Required for Inhibition of the Antiapoptotic Function of Bcl-xL

John E. Harlan, Ameeta Kelekar, Stephen W. Fesik, 1999, Molecular and Cellular Biology.

siRNA-mediated off-target gene silencing triggered by a 7 nt complementation

Xiaoan Ruan, S. Fesik, Mark G. Anderson, 2005, Nucleic acids research.

Synergistic action of WDR5 and HDM2 inhibitors in SMARCB1-deficient cancer cells

S. Fesik, D. Flaherty, Qi Liu, 2022, NAR cancer.

Regulation of the Apaf-1/Caspase-9 Apoptosome by Caspase-3 and XIAP*

Chaohong Sun, S. Fesik, R. Armstrong, 2003, The Journal of Biological Chemistry.

NMR structure and mutagenesis of the FADD (Mort1) death-effector domain

Stephen W. Fesik, R. Meadows, S. Fesik, 1998, Nature.

Three-dimensional structures of proteins involved in programmed cell death.

S. Fesik, H. Liang, Heng Liang, 1997, Journal of molecular biology.

The lymphoproliferation mutation in Fas locally unfolds the Fas death domain

E. Olejniczak, S. Fesik, Baohua Huang, 1997, Nature Structural Biology.

Bcl‐xL regulates apoptosis by heterodimerization‐dependent and ‐independent mechanisms

S. Fesik, M. V. Vander Heiden, C. Thompson, 1999, The EMBO journal.

Over-expression of the human MDM2 p53 binding domain by fusion to a p53 transactivation peptide.

E. Olejniczak, S. Fesik, Zhihong Liu, 2004, Protein expression and purification.

Discovery of Sulfonamide-Derived Agonists of SOS1-Mediated Nucleotide Exchange on RAS Using Fragment-Based Methods.

E. Olejniczak, S. Fesik, A. Waterson, 2020, Journal of medicinal chemistry.

Discovery and Structure-Based Optimization of Benzimidazole-Derived Activators of SOS1-Mediated Nucleotide Exchange on RAS.

S. Fesik, A. Waterson, O. Rossanese, 2018, Journal of medicinal chemistry.

Discovery of Aminopiperidine Indoles That Activate the Guanine Nucleotide Exchange Factor SOS1 and Modulate RAS Signaling.

S. Fesik, A. Waterson, O. Rossanese, 2018, Journal of medicinal chemistry.

Small Molecule–Mediated Activation of RAS Elicits Biphasic Modulation of Phospho-ERK Levels that Are Regulated through Negative Feedback on SOS1

S. Fesik, A. Waterson, O. Rossanese, 2018, Molecular Cancer Therapeutics.

Approach for targeting Ras with small molecules that activate SOS-mediated nucleotide exchange

E. Olejniczak, S. Fesik, A. Waterson, 2014, Proceedings of the National Academy of Sciences.

Bcl-xL forms an ion channel in synthetic lipid membranes

Andy J. Minn, Steven W. Muchmore, Michael Fill, 1997, Nature.

Discovery and structure-activity relationship of oxalylarylaminobenzoic acids as inhibitors of protein tyrosine phosphatase 1B.

Gang Liu, P. Hajduk, S. Fesik, 2003, Journal of medicinal chemistry.

Impact of WIN site inhibitor on the WDR5 interactome

E. Olejniczak, S. Fesik, Qi Liu, 2021, Cell reports.

Identification of Ras-related nuclear protein, targeting protein for xenopus kinesin-like protein 2, and stearoyl-CoA desaturase 1 as promising cancer targets from an RNAi-based screen.

S. Fesik, Qian Zhang, L. Tucker, 2007, Cancer research.

Defining the optimal parameters for hairpin-based knockdown constructs.

Xiaoyu Lin, Anastasia Khvorova, S. Fesik, 2007, RNA.

NMR Structures of Proteins Involved in Signal Transduction

T. Logan, R. Meadows, E. Olejniczak, 1996 .

Solution structure of the ets domain of Fli-1 when bound to DNA

R. Meadows, Liping Yu, E. Olejniczak, 1994, Nature Structural Biology.

Insights into Programmed Cell Death through Structural Biology

S. Fesik, Stephen W. Fesik, 2000, Cell.

NMR studies of the anti-apoptotic protein Bcl-xL in micelles.

E. Olejniczak, S. Fesik, S. Betz, 2000, Biochemistry.

Development of a tightly regulated U6 promoter for shRNA expression

A. Gunasekera, S. Fesik, Xiaoyu Lin, 2004, FEBS letters.

Controlling the Caspases

S. Fesik, Yigong Shi, S W Fesik, 2001, Science.

Bad is a BH3 domain-containing protein that forms an inactivating dimer with Bcl-XL

S. Fesik, C. Thompson, J. Harlan, 1997, Molecular and cellular biology.

Structural basis for binding of Smac/DIABLO to the XIAP BIR3 domain

Stephen F. Betz, Stephen W. Fesik, Edward T. Olejniczak, 2000, Nature.

Discovery of a Potent Stapled Helix Peptide That Binds to the 70N Domain of Replication Protein A

Stephen W. Fesik, Walter J. Chazin, Edward T. Olejniczak, 2014, Journal of medicinal chemistry.

Discovery of potent antagonists of the antiapoptotic protein XIAP for the treatment of cancer.

Saul H Rosenberg, Chaohong Sun, R. Meadows, 2004, Journal of medicinal chemistry.

Interaction with WDR5 promotes target gene recognition and tumorigenesis by MYC.

Qi Sun, Zhongming Zhao, Zhongming Zhao, 2015, Molecular cell.

A chemical genomics screen highlights the essential role of mitochondria in HIF-1 regulation

S. Fesik, U. Warrior, M. Michaelides, 2008, Proceedings of the National Academy of Sciences.

Solution structure of a Bcl-2 homolog from Kaposi sarcoma virus

A. Petros, E. Olejniczak, S. Fesik, 2002, Proceedings of the National Academy of Sciences of the United States of America.

Structure of a Myeloid cell leukemia-1 (Mcl-1) inhibitor bound to drug site 3 of Human Serum Albumin.

E. Olejniczak, S. Fesik, J. Sensintaffar, 2017, Bioorganic & medicinal chemistry.

Discovery of Potent Orally Bioavailable WD Repeat Domain 5 (WDR5) Inhibitors Using a Pharmacophore-Based Optimization.

S. Fesik, J. Sai, Bin Zhao, 2022, Journal of medicinal chemistry.

WIN site inhibition disrupts a subset of WDR5 function

S. Fesik, D. Flaherty, Qi Liu, 2022, Scientific Reports.

Discovery and Structure-Based Optimization of Potent and Selective WD repeat domain 5 (WDR5) Inhibitors Containing a Dihydroisoquinolinone Bicyclic Core.

S. Fesik, R. Coffey, M. Inoue, 2019, Journal of medicinal chemistry.

Targeting WDR5: A WINning Anti-Cancer Strategy?

S. Fesik, W. Tansey, A. M. Weissmiller, 2019, Epigenetics insights.

Displacement of WDR5 from Chromatin by a WIN Site Inhibitor with Picomolar Affinity

S. Fesik, M. Hall, Qi Liu, 2019, Cell reports.

Promoting apoptosis as a strategy for cancer drug discovery

S. Fesik, 2005, Nature Reviews Cancer.

Solution structure of a pleckstrin-homology domain

P. Hajduk, A. Petros, R. Meadows, 1994, Nature.

Solution structure of the cytohesin-1 (B2-1) Sec7 domain and its interaction with the GTPase ADP ribosylation factor 1.

R. Meadows, E. Olejniczak, S. Fesik, 1998, Proceedings of the National Academy of Sciences of the United States of America.

Optimization of Potent and Selective Tricyclic Indole Diazepinone Myeloid Cell Leukemia-1 Inhibitors Using Structure-Based Design.

E. Olejniczak, S. Fesik, O. Rossanese, 2018, Journal of medicinal chemistry.

Defective CD95/APO-1/Fas signal complex formation in the human autoimmune lymphoproliferative syndrome, type Ia.

M. Peter, S. Fesik, J. Puck, 1999, Proceedings of the National Academy of Sciences of the United States of America.

A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous Leukemia.

E. Olejniczak, S. Fesik, G. Ayers, 2018, Cancer discovery.

From Bacterial Genomes to Novel Antibacterial Agents: Discovery, Characterization, and Antibacterial Activity of Compounds that Bind to HI0065 (YjeE) from Haemophilus influenzae

P. Hajduk, K. Comess, Liping Yu, 2007, Chemical biology & drug design.

CPD Damage Recognition by Transcribing RNA Polymerase II

S. Korsmeyer, D. Vaux, S. Lowe, 2007 .

Solution structure of the amino-terminal fragment of urokinase-type plasminogen activator.

A. Petros, R. Meadows, E. Olejniczak, 1994, Biochemistry.

Fragment-Based Discovery of Small Molecules Bound to T-Cell Immunoglobulin and Mucin Domain-Containing Molecule 3 (TIM-3).

S. Fesik, Taekyu Lee, R. Gogliotti, 2021, Journal of medicinal chemistry.

Activity of the Bcl-2 Family Inhibitor ABT-263 in a Panel of Small Cell Lung Cancer Xenograft Models

C. Tse, S. Fesik, S. Rosenberg, 2008, Clinical Cancer Research.

Solution structure and function of a conserved protein SP14.3 encoded by an essential Streptococcus pneumoniae gene.

A. Gunasekera, E. Olejniczak, S. Fesik, 2001, Journal of molecular biology.

Model for mammalian metallothionein structure.

S. Fesik, Y. Boulanger, C. Forte, 1983, Proceedings of the National Academy of Sciences of the United States of America.

Solution structure of the BHRF1 protein from Epstein-Barr virus, a homolog of human Bcl-2.

A. Petros, E. Olejniczak, S. Fesik, 2003, Journal of molecular biology.

Deoxydative substitution of pyridine 1-oxides. 18. Tetrahydropyridines from 3-picoline 1-oxide and tert-butyl and 1-adamantyl mercaptan in acetic anhydride. Structural elucidation by long range 2D J(C-H) resolved NMR spectroscopy

S. Fesik, L. Bauer, Supaluk Prachayasittikul, 1985 .

Tetrahydropyridines from 3-picoline 1-oxide and tert-butyl and 1-adamantyl mercaptans in acetic anhydride: structural elucidation by long-range 2D J(C-H) resolved NMR spectroscopy

S. Fesik, L. Bauer, Supaluk Prachayasittikul, 1985 .

High-throughput screening identifies small molecules that bind to the RAS:SOS:RAS complex and perturb RAS signaling.

S. Fesik, A. Waterson, O. Rossanese, 2018, Analytical biochemistry.

A method for the second-site screening of K-Ras in the presence of a covalently attached first-site ligand

E. Olejniczak, S. Fesik, A. Friberg, 2014, Journal of Biomolecular NMR.

Discovery of small molecules that bind to K-Ras and inhibit Sos-mediated activation.

Qi Sun, Stephen W. Fesik, Edward T. Olejniczak, 2012, Angewandte Chemie.

Small Molecule SOS1 Agonists Modulate MAPK and PI3K Signaling via Independent Cellular Responses.

E. Olejniczak, S. Fesik, A. Waterson, 2019, ACS chemical biology.

Equilibrium denaturation of recombinant human FK binding protein in urea.

D. Egan, T. Logan, T. Holzman, 1993, Biochemistry.

1H,13C and 15N backbone assignments of cyclophilin when bound to cyclosporin A (CsA) and preliminary structural characterization of the CsA binding site

T. Logan, R. Meadows, E. Olejniczak, 1991, FEBS letters.

Three-dimensional 13C-resolved proton NOE spectroscopy of uniformly 13C-labeled proteins for the NMR assignment and structure determination of larger molecules

F. Dahlquist, S. Fesik, L. McIntosh, 1990 .

Heteronuclear three-dimensional nmr spectroscopy. A strategy for the simplification of homonuclear two-dimensional NMR spectra

S. Fesik, E. Zuiderweg, 1988 .

Application of isotope-filtered 2D NOE experiments in the conformational analysis of atrial natriuretic factor(7–23)

S. Fesik, R. Gampe, T. Rockway, 1987 .

Stereospecific assignments of glycine in proteins by stereospecific deuteration and 15N labeling

Stephen W. Fesik, S. Fesik, Robert W. Jr. Curley, 1994, Journal of biomolecular NMR.

1H, 13C, and 15N assignments and secondary structure of the FK506 binding protein when bound to ascomycin

R. Meadows, E. Olejniczak, S. Fesik, 1993, Biopolymers.

Three-dimensional structure of the FK506 binding protein/ascomycin complex in solution by heteronuclear three- and four-dimensional NMR.

A. Petros, R. Meadows, E. Olejniczak, 1993, Biochemistry.

Changes in the NMR-derived motional parameters of the insulin receptor substrate 1 phosphotyrosine binding domain upon binding to an interleukin 4 receptor phosphopeptide.

E. Olejniczak, S. Fesik, M. Zhou, 1997, Biochemistry.

Backbone dynamics of the C-terminal domain of Escherichia coli topoisomerase I in the absence and presence of single-stranded DNA.

S. Fesik, Y. Tse‐Dinh, L. Yu, 1996, Biochemistry.

The Use of Differential Chemical Shifts for Determining the Binding Site Location and Orientation of Protein-Bound Ligands

Stephen W. Fesik, Philip J. Hajduk, P. Hajduk, 2000 .

NMR studies of molecular complexes as a tool in drug design.

S. Fesik, S W Fesik, 1991, Journal of medicinal chemistry.

NMR-based discovery of phosphotyrosine mimetics that bind to the Lck SH2 domain.

P. Hajduk, S. Fesik, M. Zhou, 1999, Bioorganic & medicinal chemistry letters.

Interaction with WDR 5 Pro motes Target Gene Recognition and Tumorigenesis by MYC Graphical

Zhongming Zhao, E. Olejniczak, S. Fesik, 2015 .

WDR5 is a conserved regulator of protein synthesis gene expression

S. Fesik, D. Flaherty, Qi Liu, 2020, Nucleic acids research.

ABT-263 and rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo

C. Tse, S. Fesik, S. Chemburkar, 2008, Molecular Cancer Therapeutics.

Fragment-based drug discovery using NMR spectroscopy

Stephen W. Fesik, S. Fesik, M. Harner, 2013, Journal of biomolecular NMR.

Structure of the N-terminal RNA-binding domain of the SARS CoV nucleocapsid protein.

A. Gunasekera, P. Hajduk, A. Petros, 2004, Biochemistry.

Discovery of aminoglycoside mimetics by NMR-based screening of Escherichia coli A-site RNA.

Liping Yu, S. Fesik, Jianguo Yang, 2003, Journal of the American Chemical Society.

Structure-based discovery of potent WD repeat domain 5 inhibitors that demonstrate efficacy and safety in preclinical animal models

S. Fesik, Qi Liu, S. Chowdhury, 2022, Proceedings of the National Academy of Sciences of the United States of America.

Discovery and Optimization of Salicylic Acid-Derived Sulfonamide Inhibitors of the WD Repeat-Containing Protein 5 (WDR5)-MYC Protein-Protein Interaction.

S. Fesik, A. Waterson, O. Rossanese, 2019, Journal of medicinal chemistry.

NMR-based screening in drug discovery

P. Hajduk, R. Meadows, S. Fesik, 1999, Quarterly Reviews of Biophysics.

Diphenylpyrazoles as replication protein a inhibitors.

S. Fesik, B. Vangamudi, A. Waterson, 2015, ACS medicinal chemistry letters.

Discovery of a potent inhibitor of replication protein a protein-protein interactions using a fragment-linking approach.

S. Fesik, B. Vangamudi, A. Waterson, 2013, Journal of medicinal chemistry.

Surface reengineering of RPA70N enables cocrystallization with an inhibitor of the replication protein A interaction motif of ATR interacting protein.

S. Fesik, B. Vangamudi, A. Waterson, 2013, Biochemistry.

Discovery of Protein-Protein Interaction Inhibitors of Replication Protein A.

S. Fesik, B. Vangamudi, A. Waterson, 2013, ACS medicinal chemistry letters.

A high-throughput fluorescence polarization anisotropy assay for the 70N domain of replication protein A.

E. Olejniczak, S. Fesik, O. Rossanese, 2012, Analytical biochemistry.

Solution structure of an rRNA methyltransferase (ErmAM) that confers macrolide-lincosamide-streptogramin antibiotic resistance

Jean M. Severin, A. Petros, Liping Yu, 1997, Nature Structural Biology.

Stereospecific assignments and chi 1 rotamers for FKBP when bound to ascomycin from 3JH alpha,H beta and 3HN,H beta coupling constants.

E. Olejniczak, S. Fesik, R. Xu, 1992, FEBS letters.

Fragment-based screening of programmed death ligand 1 (PD-L1).

E. Olejniczak, S. Fesik, Bin Zhao, 2019, Bioorganic & medicinal chemistry letters.

Fragment-Based Screening of the Bromodomain of ATAD2

Brian A. Chauder, S. Fesik, B. Chauder, 2014, Journal of medicinal chemistry.

The secondary structure of the ets domain of human Fli-1 resembles that of the helix-turn-helix DNA-binding motif of the Escherichia coli catabolite gene activator protein.

E. Olejniczak, S. Fesik, C. Thompson, 1994, Proceedings of the National Academy of Sciences of the United States of America.

The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo

Saul H. Rosenberg, Stephen W. Fesik, C. Tse, 2010, Cancer Chemotherapy and Pharmacology.

Interaction of the oncoprotein transcription factor MYC with its chromatin cofactor WDR5 is essential for tumor maintenance

S. Fesik, Qi Liu, C. M. Eischen, 2019, Proceedings of the National Academy of Sciences.

Survivin depletion preferentially reduces the survival of activated K-Ras-transformed cells

S. Fesik, S. Shirasawa, T. Sasazuki, 2007, Molecular Cancer Therapeutics.

Discovery and biological characterization of potent myeloid cell leukemia‐1 inhibitors

A. Letai, E. Olejniczak, S. Fesik, 2017, FEBS letters.

High-level expression of recombinant human FK-binding protein from a fusion precursor

Jean M. Severin, N. Burres, A. Petros, 1992, Journal of protein chemistry.

Structural characterization of the FK506 binding protein unfolded in urea and guanidine hydrochloride.

Y. Thériault, T. Logan, S. Fesik, 1994, Journal of molecular biology.

NMR and mutagenesis evidence for an I domain allosteric site that regulates lymphocyte function-associated antigen 1 ligand binding.

J. R. Huth, E. Olejniczak, S. Fesik, 2000, Proceedings of the National Academy of Sciences of the United States of America.

A model of the cyclophilin/cyclosporin A (CSA) complex from NMR and X-ray data suggests that CSA binds as a transition-state analog

Stephen W. Fesik, Edward T. Olejniczak, R. Meadows, 1992 .

C-TERMINAL DOMAIN OF ESCHERICHIA COLI TOPOISOMERASE I

Liping Yu, S. Fesik, Y. Tse‐Dinh, 1996 .

Stromelysin Inhibitors Designed from Weakly Bound Fragments: Effects of Linking and Cooperativity

P. Hajduk, R. Meadows, E. Olejniczak, 1997 .

ChemInform Abstract: Discovery of Potent Nonpeptide Inhibitors of Stromelysin Using SAR by NMR.

Karl A. Walter, Jean M. Severin, Stephen W. Fesik, 1997 .

A Strategy for High-Throughput Assay Development Using Leads Derived from Nuclear Magnetic Resonance-Based Screening

P. Hajduk, Xiaoan Ruan, S. Fesik, 2002, Journal of biomolecular screening.

Discovery of a potent and selective Bcl-2 inhibitor using SAR by NMR.

Renaldo Mendoza, Saul H Rosenberg, Cheol-Min Park, 2010, Bioorganic & medicinal chemistry letters.

Accurate measurement of H(N)-H(alpha) residual dipolar couplings in proteins.

A. Gunasekera, R. Meadows, E. Olejniczak, 1999, Journal of magnetic resonance.

Discovery of Potent Myeloid Cell Leukemia-1 (Mcl-1) Inhibitors That Demonstrate in Vivo Activity in Mouse Xenograft Models of Human Cancer.

E. Olejniczak, S. Fesik, J. Opferman, 2019, Journal of medicinal chemistry.

Targeting MYC through WDR5

S. Fesik, C. M. Eischen, C. Adams, 2020, Molecular & cellular oncology.

NMR study of the possible interaction in solution of angiotensin II with a peptide encoded by angiotensin II complementary RNA.

S. Fesik, R. Austin, H. Eaton, 1989, Proceedings of the National Academy of Sciences of the United States of America.

Geometric requirements for membrane perturbation and anesthetic activity. Conformational analysis of alphaxalone and delta 16-alphaxalone and 2H NMR studies on their interactions with model membranes.

S. Fesik, A. Makriyannis, 1985, Molecular pharmacology.

MECHANISM OF STEROID ANESTHETIC ACTION: INTERACTIONS OF ALPHAXALONE AND Δ16-ALPHAXALONE WITH BILAYER VESICLES

S. Fesik, A. Makriyannis, 1983 .

Ligand binding to domain-3 of human serum albumin: a chemometric analysis

Yvonne C. Martin, Mark G. Bures, Jeffrey R. Huth, 2003, J. Comput. Aided Mol. Des..

Structure refinement of a cyclic peptide from two-dimensional NMR data and molecular modeling.

E. Olejniczak, S. Fesik, H. Sham, 1987, Biochemistry.

NMR-Based Screening of Proteins Containing 13C-Labeled Methyl Groups

Renaldo Mendoza, Stephen W. Fesik, Philip J. Hajduk, 2000 .

Design of adenosine kinase inhibitors from the NMR-based screening of fragments.

Jean M. Severin, E A Kowaluk, P. Hajduk, 2000, Journal of medicinal chemistry.

Isotope-edited proton NMR study on the structure of a pepsin/inhibitor complex.

S. Fesik, C. Abad-Zapatero, J. Erickson, 1988, Biochemistry.

1H Assignments of glycopeptide antibiotics by double quantum NMR and relayed correlation spectroscopy

S. Fesik, T. Perun, Alford M. Thomas, 1985 .

Ribosome subunit attrition and activation of the p53–MDM4 axis dominate the response of MLL-rearranged cancer cells to WDR5 WIN site inhibition

Kristie L. Rose, S. Fesik, Qi Liu, 2023, bioRxiv.

A method for the second-site screening of K-Ras in the presence of a covalently attached first-site ligand

E. Olejniczak, S. Fesik, A. Friberg, 2014, Journal of Biomolecular NMR.

Isotope-edited NMR spectroscopy

S. Fesik, 1988, Nature.

Understanding the Species Selectivity of Myeloid Cell Leukemia-1 (Mcl-1) Inhibitors.

E. Olejniczak, S. Fesik, Bin Zhao, 2018, Biochemistry.

Discovery of tricyclic indoles that potently inhibit Mcl-1 using fragment-based methods and structure-based design.

Anders Friberg, Bin Zhao, E. Olejniczak, 2015, Journal of medicinal chemistry.

NMR study of the solution conformation of rat atrial natriuretic factor 7-23 in sodium dodecyl sulfate micelles.

E. Olejniczak, S. Fesik, R. Gampe, 1988, Biochemistry.

Discovery of WD Repeat-Containing Protein 5 (WDR5)-MYC inhibitors using fragment-based methods and structure-based design.

E. Olejniczak, S. Fesik, A. Waterson, 2020, Journal of medicinal chemistry.

An approach for high-throughput structure determination of proteins by NMR spectroscopy

A Medek, R. Meadows, E. Olejniczak, 2000, Journal of biomolecular NMR.

NMR-based modification of matrix metalloproteinase inhibitors with improved bioavailability.

Yan Guo, Michael Michaelides, Richard Craig, 2002, Journal of medicinal chemistry.

Effects of anesthetics on sulfate transport in the red cell

S. Fesik, A. Makriyannis, Stephen W. Fesik, 1980, Journal of neuroscience research.

PD-L1 IgV domain V76T with fragment

E. Olejniczak, S. Fesik, Bin Zhao, 2019 .

ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor.

S. Fesik, Eric F. Johnson, S. Rosenberg, 2008, Cancer research.

ABT-263 and rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo

S. Fesik, S. Chemburkar, S. Rosenberg, 2008, Molecular Cancer Therapeutics.

Conformation of two non‐immunosuppressive FK506 analogs when bound to FKBP by isotope‐filtered NMR

A. Petros, S. Fesik, J. Luly, 1992, FEBS letters.

Amide proton exchange rates of a bound pepsin inhibitor determined by isotope-edited proton NMR experiments.

S. Fesik, J. Luly, H. Stein, 1987, Biochemical and biophysical research communications.

Interaction with WDR5 promotes target gene recognition and tumorigenesis by MYC.

E. Olejniczak, S. Fesik, C. M. Eischen, 2015, Molecular cell.

Stereospecific assignments and χ1 rotamers for FKBP when bound to ascomycin from 3 J Hα,Hβ and 3 J N,Hβ coupling constants

Stephen W. Fesik, Edward T. Olejniczak, E. Olejniczak, 1992 .

A method for measuring 1H-1H coupling constants in 13C-labeled molecules

S. Fesik, G. Gemmecker, 1991 .

A computer-based protocol for semiautomated assignments and 3D structure determination of proteins

Stephen W. Fesik, Edward T. Olejniczak, R. Meadows, 1994, Journal of biomolecular NMR.

Optimized constant-time 4D HNCAHA and HN(CO)CAHA experiments. Applications to the backbone assignments of the FKBP/ascomycin complex

A. Petros, E. Olejniczak, S. Fesik, 1992 .

Four-dimensional [13C,1H,13C,1H] HMQC-NOE-HMQC NMR spectroscopy: resolving tertiary nuclear Overhauser effect distance constraints in the spectra of larger proteins

A. Petros, E. Olejniczak, S. Fesik, 1991 .

Diphenylpyrazoles as replication protein a inhibitors.

S. Fesik, B. Vangamudi, A. Waterson, 2015, ACS medicinal chemistry letters.

Discovery of Protein-Protein Interaction Inhibitors of Replication Protein A.

S. Fesik, B. Vangamudi, A. Waterson, 2013, ACS medicinal chemistry letters.

Isotope-filtered proton NMR experiments for the conformational determination of peptides in solution and bound to biomacromolecules

E. Olejniczak, S. Fesik, R. Gampe, 1988 .

Improved NMR Structures of Protein/Ligand Complexes Using Residual Dipolar Couplings

R. Meadows, E. Olejniczak, S. Fesik, 1999 .

Discovery and structure-activity relationship of oxalylarylaminobenzoic acids as inhibitors of protein tyrosine phosphatase 1B.

P. Hajduk, S. Fesik, C. Abad-Zapatero, 2003, Journal of medicinal chemistry.

Growth inhibition and radiosensitization of glioblastoma and lung cancer cells by small interfering RNA silencing of tumor necrosis factor receptor-associated factor 2.

Dafydd G. Thomas, S. Fesik, Yi Sun, 2008, Cancer research.

Discovery and structure-activity relationship of antagonists of B-cell lymphoma 2 family proteins with chemopotentiation activity in vitro and in vivo.

A. Petros, S. Fesik, S. Ng, 2006, Journal of medicinal chemistry.

Resonance-Based Screening A Strategy for High-Throughput Assay Development Using Leads Derived from Nuclear Magnetic

P. Hajduk, Xiaoan Ruan, S. Fesik, 2013 .

Nuclear magnetic resonance studies on the antibiotic avoparcin, Conformational properties in relation to antibacterial activity.

S. Fesik, G. Ellestad, I. Armitage, 1984, Molecular pharmacology.

Identification of solvent-exposed regions of enzyme-bound ligands by nuclear magnetic resonance

A. Petros, E. Olejniczak, S. Fesik, 1991 .